Drugs / Actinium Ac 225-DOTA-Daratumumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06287944 | Jul 2025 → May 2028 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05363111 | Nov 2022 → Mar 2027 expected | plasma cell myeloma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Actinium Ac 225-DOTA-Daratumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05363111 ↗ |
| Known as | 225Ac-DOTA-daratumumab | “This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab” NCT05363111 ↗ |
| Action | Deplete | “Giving all three together may kill more cancer cells.” NCT05363111 ↗ |
| Modality | Monoclonal antibody | “111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab are forms of radioimmunotherapy in which a monoclonal antibody, daratumumab, has been linked to a radiotracer to allow for...” NCT05363111 ↗ |
| Route | Intravenous | “patients receive 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab IV over 20-30 minutes.” NCT05363111 ↗ |